CClinicalTrials.gg
CompletedNCT02266030ESCAPEUpdated Oct 9, 2017

Effect of Cilostazol on Coronary Artery Stenosis and Plaque Characteristics in Patients With T2DM

A Phase 3 interventional study of Cilostazol and Aspirin in Coronary Artery Disease, sponsored by Seoul National University Bundang Hospital. Completed at 1 site in Korea, Republic of. Open to participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-10-09.

Sponsored by Seoul National University Bundang Hospital · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
30 Years to 80 Years
Sex
All
01

Study summary

This is a prospective interventional study to assess the effect of cilostazol compared with aspirin in Korean T2DM patients with atherosclerosis.

Read the detailed description

Type 2 diabetes has been increased exponentially, arousing serious economic, social and health repercussions. Also, macrovascular complications of diabetes such as myocardial infarct or stroke have been increased. Individuals with diabetes have a greater risk of cardiovascular disease (CVD), approximately two to four times than that of those without diabetes. Currently, the U.S. Food and Drug Administration requires demonstration that new anti-hyperglycemic agents do not increase CV risk. The comprehensive and multifactorial management in type 2 diabetes, which includes control of hypertension, dyslipidemia and obesity, is known to significantly reduce the risk of CVD as shown in Steno-2 study. However, most anti-diabetic agents currently used in clinical practice do not seem to provide enough CV protection.

This is a prospective interventional study to assess the effect of cilostazol compared with aspirin in Korean T2DM patients with atherosclerosis. T2DM patients who have coronary artery stenosis by MDCT at least 3 months prior to this investigation will be enrolled.

Considering drop out due to adverse events or follow up loss, sufficient patients will be enrolled. Their medical record will be reviewed and relevant clinical and laboratory findings will be collected.

Cardiac computed tomography (CT) was introduced in the early 1990s. However, electron-beam CT (EBCT) only provided information on simple coronary artery calcium score (CAC). Recently, MDCT has been introduced, which can evaluate coronary arteries comprehensively. MDCT images can provide measurements of CAC, the degree of stenosis, and the characteristics of plaque including its potential vulnerability. These findings of MDCT have been reported to be in good agreement with intravascular ultrasound.

All scans are analyzed independently by two experienced investigators using a 3D workstation, who are blinded to the clinical information (Brilliance; Philips Medical Systems). After independent evaluations are made, a consensus interpretation is arrived at regarding the final MDCT diagnosis. Each lesion is identified using a multiplanar reconstruction technique and maximum intensity projection of the short axis, in two-chamber and four-chamber views. Image quality is evaluated on a per-segment basis and classified. Plaque characteristics on a per-segment basis are analyzed according to the modified American Heart Association classification.

02

Conditions studied

  • Coronary Artery Disease
03

In context

Coronary Artery Disease

5,598 studies on the registry are indexed under Coronary Artery Disease; 957 are open to participants now.

This study's enrollment of 100 is below the median of 124 across 3,436 interventional studies indexed under Coronary Artery Disease.

Browse Coronary Artery Disease studies →

Lead sponsor

Seoul National University Bundang Hospital is the lead sponsor of 368 studies on the registry; 55 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Type 2 diabetes with HbA1c ≥ 6.0% at screening visit
  • Male or female between 30 and 80 years of age
  • Coronary artery stenosis: 25-75% without no evidence of acute coronary syndrome
  • No history of previous myocardial infarction
  • Estimated GFR ≥ 60 ml/min/1.73m²

Exclusion criteria

Exclusion Criteria:

  • SBP/DBP> 160/110
  • Congestive heart failure
  • Allegy to radiocontrast dye
  • Allegy to aspirin or cilostazol
  • Acute bleeding
  • History of ulcer bleeding
  • GOT/GPT > 100/100
  • Other antiplatlet medication
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Cilostazol

    Cilostazol 100-200 mg qd

    Drug: Cilostazol

  • Active comparator
    Aspirin

    Asprin 100mg qd for active comparator

    Drug: Aspirin

Interventions

  • DrugCilostazol

    Pletaal as an active drug

    Also known as: Pletaal

  • DrugAspirin

    Aspirin as an active comparator

06

What researchers measure

Primary outcomes

  1. Coronary artery stenosis

    Severity of coronary artery stenosis (%)

    Time frame: one year

Secondary outcomes

  1. Plaque characteristics

    Noncalified plaque

    Time frame: one year

  2. Plaque characteristics

    Mixed plaque

    Time frame: one year

  3. Plaque characteristics

    Calcified plaque

    Time frame: one year

  4. Multivessel involvement

    Multivessel involvement in coronary arteries

    Time frame: one year

  5. Main vessel involvement

    Left main and/or proximal LAD stenosis

    Time frame: one year

  6. Coronary artery calcium (CAC) score

    Agatston score for CAC

    Time frame: one year

  7. Glucose homeostasis

    Changes in HbA1c

    Time frame: one year

  8. Glucose homeostasis

    Changes in fasting glucose concentration

    Time frame: one year

  9. Lipid metabolism

    Changes in TG concentration

    Time frame: one year

  10. Lipid metabolism

    Changes in HDL-concentration concentration

    Time frame: one year

Other outcomes

  1. Bleeding risk

    Any type of bleeding

    Time frame: one year

  2. Headache

    Any type of headache

    Time frame: one year

  3. Heart rate

    Frequence of heart beat per min

    Time frame: one year

07

Study locations

1 site
  • Seoul National University Bundang Hospital
    Seongnam, Bundang-gu 463-707, Korea, Republic of
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 9, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02266030
Lead sponsor
Seoul National University Bundang Hospital
Responsible party
Soo Lim (Professor, Seoul National University Bundang Hospital) — Principal investigator
First posted
Oct 16, 2014
Start date
Feb 2011
Primary completion
Nov 2016
Completion
Nov 2016
Last update
Oct 9, 2017

Study contacts

Soo Lim, MD, PhD
principal investigator · SNUBH

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion